80 related articles for article (PubMed ID: 17719748)
1. The current status and future direction of percutaneous peptide immunization against melanoma.
Seo N; Takigawa M
J Dermatol Sci; 2007 Nov; 48(2):77-85. PubMed ID: 17719748
[TBL] [Abstract][Full Text] [Related]
2. Induction of therapeutically relevant cytotoxic T lymphocytes in humans by percutaneous peptide immunization.
Yagi H; Hashizume H; Horibe T; Yoshinari Y; Hata M; Ohshima A; Ito T; Takigawa M; Shibaki A; Shimizu H; Seo N
Cancer Res; 2006 Oct; 66(20):10136-44. PubMed ID: 17047078
[TBL] [Abstract][Full Text] [Related]
3. Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis.
Takigawa M; Tokura Y; Hashizume H; Yagi H; Seo N
Ann N Y Acad Sci; 2001 Sep; 941():139-46. PubMed ID: 11594567
[TBL] [Abstract][Full Text] [Related]
4. Differential capacity of chaperone-rich lysates in cross-presenting human endogenous and exogenous melanoma differentiation antigens.
Bleifuss E; Bendz H; Sirch B; Thompson S; Brandl A; Milani V; Graner MW; Drexler I; Kuppner M; Katsanis E; Noessner E; Issels RD
Int J Hyperthermia; 2008 Dec; 24(8):623-37. PubMed ID: 18608582
[TBL] [Abstract][Full Text] [Related]
5. In vivo anti-melanoma activities of the Melan-A/MART-1(101-115) T CD4+ cell peptide.
Balasse E; Gatouillat G; Patigny D; Andry MC; Madoulet C
Vaccine; 2009 Oct; 27(44):6107-9. PubMed ID: 19686694
[TBL] [Abstract][Full Text] [Related]
6. Magnetic separation of melanoma-specific cytotoxic T lymphocytes from a vaccinated melanoma patient's blood using MHC/peptide complex-conjugated bacterial magnetic particles.
Takahashi M; Akiyama Y; Ikezumi J; Nagata T; Yoshino T; Iizuka A; Yamaguchi K; Matsunaga T
Bioconjug Chem; 2009 Feb; 20(2):304-9. PubMed ID: 19143499
[TBL] [Abstract][Full Text] [Related]
7. Active-specific immunization against melanoma: is the problem at the receiving end?
Monsurrò V; Wang E; Panelli MC; Nagorsen D; Jin P; Katia Z; Smith K; Ngalame Y; Even J; Marincola FM
Semin Cancer Biol; 2003 Dec; 13(6):473-80. PubMed ID: 15001166
[TBL] [Abstract][Full Text] [Related]
8. The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells.
Fujisawa Y; Nabekura T; Nakao T; Nakamura Y; Takahashi T; Kawachi Y; Otsuka F; Onodera M
Exp Dermatol; 2009 Apr; 18(4):396-403. PubMed ID: 19054057
[TBL] [Abstract][Full Text] [Related]
9. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E
J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017
[TBL] [Abstract][Full Text] [Related]
10. Immunohistological analysis of peptide-induced delayed-type hypersensitivity in advanced melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
Nakai N; Katoh N; Germeraad WT; Kishida T; Ueda E; Takenaka H; Mazda O; Kishimoto S
J Dermatol Sci; 2009 Jan; 53(1):40-7. PubMed ID: 18804963
[TBL] [Abstract][Full Text] [Related]
11. Tumor immunotherapy in melanoma: on the dawn of a new era?
Wilcox R; Markovic SN
Curr Opin Mol Ther; 2007 Feb; 9(1):70-8. PubMed ID: 17330404
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cell vaccines in melanoma: from promise to proof?
Lesterhuis WJ; Aarntzen EH; De Vries IJ; Schuurhuis DH; Figdor CG; Adema GJ; Punt CJ
Crit Rev Oncol Hematol; 2008 May; 66(2):118-34. PubMed ID: 18262431
[TBL] [Abstract][Full Text] [Related]
13. Purification of melanoma reactive T cell by using a monocyte-based solid phase T-cell selection system for adoptive therapy.
Li J; Mookerjee B; Wagner J
J Immunother; 2008 Jan; 31(1):81-8. PubMed ID: 18157015
[TBL] [Abstract][Full Text] [Related]
14. The anti-tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides.
Zhang XM; Zhang YF; Huang Y; Qu P; Ma B; Si SY; Li ZS; Li WX; Li X; Ge W; Hu PZ; Sui YF
Oncol Rep; 2008 Jul; 20(1):245-52. PubMed ID: 18575744
[TBL] [Abstract][Full Text] [Related]
15. Adoptive transfer of pTRP2-specific CTLs expanding by bead-based artificial antigen-presenting cells mediates anti-melanoma response.
Lu X; Jiang X; Liu R; Zhao H; Liang Z
Cancer Lett; 2008 Nov; 271(1):129-39. PubMed ID: 18621475
[TBL] [Abstract][Full Text] [Related]
16. Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients.
Molenkamp BG; Sluijter BJ; van Leeuwen PA; Santegoets SJ; Meijer S; Wijnands PG; Haanen JB; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
Clin Cancer Res; 2008 Jul; 14(14):4532-42. PubMed ID: 18628468
[TBL] [Abstract][Full Text] [Related]
17. Induction of protective CTL immunity against peptide transporter TAP-deficient tumors through dendritic cell vaccination.
Chambers B; Grufman P; Fredriksson V; Andersson K; Roseboom M; Laban S; Camps M; Wolpert EZ; Wiertz EJ; Offringa R; Ljunggren HG; van Hall T
Cancer Res; 2007 Sep; 67(18):8450-5. PubMed ID: 17875682
[TBL] [Abstract][Full Text] [Related]
18. Vaccine therapy for cutaneous T-cell lymphoma.
Seo N; Furukawa F; Tokura Y; Takigawa M
Hematol Oncol Clin North Am; 2003 Dec; 17(6):1467-74. PubMed ID: 14710897
[TBL] [Abstract][Full Text] [Related]
19. Melanoma vaccines.
Chapman PB
Semin Oncol; 2007 Dec; 34(6):516-23. PubMed ID: 18083375
[TBL] [Abstract][Full Text] [Related]
20. Immunoregulatory T cells in the peripheral blood of melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
Nakai N; Katoh N; Kitagawa T; Ueda E; Takenaka H; Kishimoto S
J Dermatol Sci; 2009 Apr; 54(1):31-7. PubMed ID: 19157789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
